📇 Rhumatologue · PARIS CEDEX 13 · (75) · Hospitalier
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
5 raisons identifiées
Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Encadrant universitaire
Forme la prochaine génération de rhumatologues (6 thèses dirigées)
Praticien-chercheur
14 articles scientifiques publiés — formation continue solide
Expérience confirmée
34 ans d'exercice en rhumatologie — recul clinique solide
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
34ans d'exercice (thèse 1992)
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
✨ Génération du profil synthétique IA en cours…
Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.
Facteurs minimaux permettant la myélinisation
2025Doctorant·e : Noémie Frère
Mechanism of microglia-neuron interaction at the node of Ranvier
2022Doctorant·e : Rémi Ronzano
Microglia-nodes of Ranvier interaction during repair
2020Doctorant·e : Thomas Roux
Dynamics of nodes of Ranvier assembly during myelination and remyelination in the central nervous system
2018Doctorant·e : Melina Thetiot
Identification des facteurs oligodendrogliaux sécrétés impliqués dans la formation des Nœuds de Ranvier du Système Nerveux Central
2018Doctorant·e : Anne-Laure Dubessy
Mechanisms of central nervous system nodes of Ranvier assembly
2015Doctorant·e : Sean Freeman
Source theses.fr — signal de direction d'équipe / statut PU-PH (à confirmer via le site universitaire).
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
69
69 articles ont été cités au moins 69fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
25 471
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
352
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
178
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Centre National de la Recherche Scientifique · Inserm · Sorbonne Université
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Cerebellar encephalitis and peripheral neuropathy with an atypical clinical and neuroimaging signature following Covid-19 vaccine: a report of two cases Authors
2024ArticleJournal of Neurology
High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS
2024ArticleJAMA neurology
Correction: Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19
2024ArticleGenome Medicine
Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19
2023ArticleGenome Medicine
The radiologically isolated syndrome: revised diagnostic criteria
2023ArticleBrain - A Journal of Neurology
Monitoring recovery after CNS demyelination, a novel tool to de-risk pro-remyelinating strategies
2023ArticleBrain - A Journal of Neurology
Alterations of the axon initial segment in multiple sclerosis grey matter
2022ArticleBrain Communications
Genetically modified macrophages accelerate myelin repair
2022ArticleEMBO Molecular Medicine
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
GHU APHP SUN SITE PITIE SALPETRIERE
47-83 47 BD DE L HOPITAL, 75651 PARIS CEDEX 13
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Brain : a journal of neurology · 2019
Abstract MRI has improved the diagnostic work-up of multiple sclerosis, but inappropriate image interpretation and application of MRI diagnostic criteria contribute to misdiagnosis. Some diseases, now recognized as conditions distinct from multiple sclerosis, may satisfy the MRI criteria for multiple sclerosis (e.g. neuromyelitis optica spectrum disorders, Susac syndrome), thus making the diagnosis of multiple sclerosis more challenging, especially if biomarker testing (such as serum anti-AQP4 antibodies) is not informative. Improvements in MRI technology contribute and promise to better define the typical features of multiple sclerosis lesions (e.g. juxtacortical and periventricular location, cortical involvement). Greater understanding of some key aspects of multiple sclerosis pathobiology has allowed the identification of characteristics more specific to multiple sclerosis (e.g. central vein sign, subpial demyelination and lesional rims), which are not included in the current multiple sclerosis diagnostic criteria. In this review, we provide the clinicians and researchers with a practical guide to enhance the proper recognition of multiple sclerosis lesions, including a thorough definition and illustration of typical MRI features, as well as a discussion of red flags suggestive of alternative diagnoses. We also discuss the possible place of emerging qualitative features of lesions which may become important in the near future.
Multiple sclerosis (Houndmills, Basingstoke, England) · 2021
Background: REFINE was an exploratory, dose- and frequency-blinded, prospective, randomized, dose-ranging study in relapsing–remitting multiple sclerosis (RRMS) patients. Objective: To examine the efficacy, safety, and tolerability of natalizumab administered via various regimens in RRMS patients. Methods: Clinically stable RRMS patients previously treated with 300 mg natalizumab intravenously for ⩾12 months were randomized to one of six natalizumab regimens over 60 weeks: 300 mg administered intravenously or subcutaneously every 4 weeks (Q4W), 300 mg intravenously or subcutaneously every 12 weeks (Q12W), or 150 mg intravenously or subcutaneously Q12W. The primary endpoint was the mean cumulative number of combined unique active magnetic resonance imaging (MRI) lesions at week 60. Results: In total, 290 patients were enrolled. All Q12W dosing arms were associated with increased clinical and MRI disease activity and closed early; ⩾39.5% of patients in each Q12W arm met rescue criteria. In the 300 mg intravenous and subcutaneous Q4 W arms, the mean cumulative number of combined unique active MRI lesions was 0.23 and 0.02, respectively; annualized relapse rates were 0.07 and 0.08, respectively; and trough natalizumab serum levels and α4-integrin saturation were comparable. Conclusion: Natalizumab 300 mg subcutaneous Q4W was comparable to 300 mg intravenous Q4W dosing with respect to efficacy, pharmacokinetics/pharmacodynamics, and safety.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Multiple sclerosis and related disorders · 2024 · Journal Article
Sahloul O, Louapre C, Beigneux Y, Lubetzki C, et al.
Multiple sclerosis (Houndmills, Basingstoke, England) · 2024 · Journal Article
Maillart E, Redolfi S, Louapre C, Houot M, et al.
EMBO molecular medicine · 2022 · Journal Article
Aigrot MS, Barthelemy C, Moyon S, Dufayet-Chaffaud G, et al.
Neurology(R) neuroimmunology & neuroinflammation · 2021 · Case Reports
Shambrook P, Hesters A, Marois C, Zemba D, et al.
JAMA neurology · 2020 · Journal Article
Louapre C, Collongues N, Stankoff B, Giannesini C, et al.
Multiple sclerosis (Houndmills, Basingstoke, England) · 2020 · Journal Article
Lünemann JD, Diaz-Diaz J, Stankoff B, Young C, et al.
Journal of neurology · 2019 · Journal Article
Lebrun-Frenay C, Moulignier A, Pierrot-Deseilligny C, Benrabah R, et al.
JAMA network open · 2021 · Journal Article
Lambrecq V, Hanin A, Munoz-Musat E, Chougar L, et al.
Brain : a journal of neurology · 2019 · Journal Article
Filippi M, Preziosa P, Banwell BL, Barkhof F, et al.
Multiple sclerosis (Houndmills, Basingstoke, England) · 2019 · Journal Article
Durozard P, Maarouf A, Boutiere C, Ruet A, et al.
Multiple sclerosis (Houndmills, Basingstoke, England) · 2021 · Journal Article
Trojano M, Ramió-Torrentà L, Grimaldi LM, Lubetzki C, et al.
Neurology(R) neuroimmunology & neuroinflammation · 2021 · Journal Article
Sterlin D, Larsen M, Fadlallah J, Parizot C, et al.
Neurology · 2021 · Journal Article
Dubessy AL, Tezenas du Montcel S, Viala F, Assouad R, et al.
Neurology · 2019 · Comparative Study
Laplaud DA, Casey R, Barbin L, Debouverie M, et al.
False hepatitis B and C viral serologies in patients with multiple sclerosis receiving high-dose biotin
Daily high-dose biotin (HDB) has been suggested to improve disability in patients with progressive multiple sclerosis (P-MS) in a small-size controlled trial conducted in France, with good tolerance.<sup>1</sup> This led
Risk factors and prognosis of orotracheal intubation in aquaporin-4-IgG neuromyelitis optica spectrum disorder attacks
Abstract Background Aquaporin-4 immunoglobulin G Neuro Myelitis Optica spectrum disorders attacks (NMOSD-AQP4-IgG+ attacks) can cause respiratory failure requiring orotracheal intubation (OTI), but the risk factors and o
False hepatitis B and C viral serologies in patients with multiple sclerosis receiving high-dose biotin
Daily high-dose biotin (HDB) has been suggested to improve disability in patients with progressive multiple sclerosis (P-MS) in a small-size controlled trial conducted in France, with good tolerance.<sup>1</sup> This led
Risk factors and prognosis of orotracheal intubation in aquaporin-4-IgG neuromyelitis optica spectrum disorder attacks
Abstract Background Aquaporin-4 immunoglobulin G Neuro Myelitis Optica spectrum disorders attacks (NMOSD-AQP4-IgG+ attacks) can cause respiratory failure requiring orotracheal intubation (OTI), but the risk factors and o
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).